Evidence map›Paper›PMID 40454714›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2025

ENaC contributes to macrophage dysfunction in cystic fibrosis.

John Moran, Courtney Pugh, Nevian Brown, Ashley Thomas, Shuzhong Zhang, Emily McCauley, Amelia Cephas, Chandra L Shrestha, Santiago Partida-Sanchez, Shasha Bai and 2 more

Abstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

John MoranCenter for Cystic Fibrosis and Airways Disease Research (CF-AIR), Emory University, Atlanta, Georgia, United States.
Courtney PughCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Nevian BrownCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.ORCID 0009-0004-4229-9124
Ashley ThomasCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Shuzhong ZhangCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Emily McCauleyCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Amelia CephasCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Chandra L ShresthaCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.
Santiago Partida-SanchezCenter for Microbial Pathogenesis, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States.ORCID 0000-0003-2996-9440
Shasha BaiPediatric Biostatistics Core, Emory University School of Medicine, Atlanta, Georgia, United States.
Emanuela BrusciaDepartment of Pediatrics, Yale School of Medicine, New Haven, Connecticut, United States.ORCID 0000-0003-2149-4057
Benjamin T KoppCenter for Cystic Fibrosis and Airways Disease Research (CF-AIR), Emory University, Atlanta, Georgia, United States.ORCID 0000-0002-2021-7990

Funding

The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Pilot & Feasibility CoreP30DK125013 · NIDDK · EMORY UNIVERSITY · PI Arlene A Stecenko · 2020 to 2026
$6.7M
The role of CFTR during macrophage-mediated killing of bacteriaR01HL148171 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Emanuela Marina Bruscia, Benjamin T Kopp · 2020 to 2026
$2.7M
Resue of CF phagocyte function with CFTR modulator therapyR01HL158747 · NHLBI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI GUGLANI, LOKESH, KOPP, BENJAMIN T · 2022 to 2025
$2.1M
Cystic Fibrosis Foundation (CFF) KOPP20I0Cystic Fibrosis Foundation (CFF) MCCOY19ROHHS | National Institutes of Health (NIH) P30-DK125013NCATS NIH HHS UL1 TR002733NHLBI NIH HHS R01 HL148171NHLBI NIH HHS R01 HL158747NIDDK NIH HHS P30 DK125013
6 · The paper itself

Abstract

Cystic fibrosis (CF) is a chronic disease caused by dysfunctional or absent cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is expressed in immune cells and regulates innate immunity, both directly and indirectly. The epithelial sodium channel (ENaC) contributes to dysfunction in CF airway epithelial cells. However, the impact of non-CFTR ion channel dysfunction on CF immune responses is not understood. Improved understanding of how immune function is regulated by ion channels may allow antibiotic- and mutation-agnostic treatment approaches to chronic infection and inflammation. Therefore, we hypothesized that ENaC is aberrantly expressed in CF macrophages and directly contributes to impaired phagocytic and inflammatory functions. ENaC expression was characterized in immune cells isolated from CF and non-CF blood donors. Monocyte-derived macrophage (MDM) function and bacterial killing were tested with ENaC modulation. Baseline ENaC expression in human CF MDMs, lymphocytes, and granulocytes was increased at both the transcript and protein level relative to non-CF and persisted after infection. CFTR inhibition in non-CF MDMs resulted in ENaC overexpression. CFTR modulator treatment reduced but did not eliminate ENaC overexpression in CF MDMs. Interestingly, ENaC inhibition increased CFTR expression. Amiloride-treated CF MDMs also showed normalized reactive oxygen species (ROS) production, improved autophagy, and decreased proinflammatory cytokine production. Sodium channel expression in CF MDMs normalized after amiloride treatment with minimal effect on other ion channels. In summary, ENaC modulation in immune cells is a novel potential therapeutic target for CF infection control, either in combination with CFTR modulators, or as a sole agent for people not eligible for CFTR modulators.

Indexed as

Cystic FibrosisEpithelial Sodium ChannelsMacrophagesCystic Fibrosis Transmembrane Conductance RegulatorFemaleHumansMalePhagocytosisReactive Oxygen SpeciesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorEpithelial Sodium ChannelsReactive Oxygen Speciescystic fibrosisimmunityion channelsmacrophagephagocyte

Identifiers

PMID40454714
PMCPMC12181047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.